Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30858424 | 0.83 | DDB1 (0.64) | DDB1CRBNMAPTKMT2AMEN1 | |
| SCHEMBL6404666 | 0.81 | MEN1 (0.56) | KMT2AMEN1SMN1; SMN2MGLLALDH1A1 | |
| SCHEMBL6399716 | 0.76 | MEN1 (0.59) | DDB1CRBNKMT2AMEN1ALOX5 | |
| SCHEMBL6399679 | 0.73 | DRD2 (0.43) | DDB1CRBNMAPTKMT2AMEN1 | |
| SCHEMBL1901693 | 0.73 | DDB1 (0.56) | DDB1CRBNMAPTKMT2AMEN1 | |
| SCHEMBL6401435 | 0.72 | L3MBTL1 (0.53) | MAPTALOX5MGLLALDH1A1 | |
| SCHEMBL12569511 | 0.71 | DDB1 (0.54) | DDB1CRBNMAPTKMT2AMEN1 | |
| SCHEMBL25575697 | 0.70 | CRBN (1.00) | DDB1CRBNMAPTKMT2AMEN1 | |
| SCHEMBL31040970 | 0.70 | CRBN (1.00) | DDB1CRBNMAPTKMT2AMEN1 | |
| SCHEMBL6399973 | 0.70 | CRBN (0.55) | CRBNKMT2AMEN1ALOX5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | DDB1 4529/4885CRBN 4692/4885MAPT 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.